Tag - BHVN

Biohaven Pharmaceutical Holding (NYSE:BHVN) reported new data from its Phase 2/3 trial of rimegepant, and orally-dosed calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraines. During the third...